Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
vincristine sulfate, Quantity: 1 mg/mL
Pfizer Australia Pty Ltd
Injection, solution
Excipient Ingredients: mannitol; water for injections; sodium hydroxide; sulfuric acid
Intravenous
5 X 2mL
(S4) Prescription Only Medicine
Vincristine is used primarily in the treatment of acute leukaemia, usually as a component of various chemotherapeutic regimens. It has also been used as part of combination therapy in the treatment of Hodgkin's disease, non-Hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, Wilm's tumour, osteogenic sarcoma, mycosis fungoides, Ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma of the lung and gynaecological tumours of childhood. Vincristine may be useful in patients with true idiopathic thrombocytopenic purpura resistant to the usual treatment, but not recommended as primary treatment for this disorder
Visual Identification: Clear and colourless solution.; Container Type: Vial; Container Material: PP; Container Life Time: 2 Years; Container Temperature: Store at 2 to 8 degrees Celsius
Registered
1994-06-22
VINCRISTINE SULFATE INJECTION _Vincristine Sulfate_ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Vincristine Sulfate Injection. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have benefits and risks. Your doctor has weighed the risks of you taking Vincristine Sulfate Injection against the benefits this medicine is expected to have for you. This medicine is likely to be used while you are at the clinic or in hospital. If possible, please read this leaflet carefully before this medicine is given to you. In some cases this leaflet may be given to you after the medicine has been used. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR, NURSE OR PHARMACIST. KEEP THIS LEAFLET. You may need to read it again. WHAT VINCRISTINE SULFATE INJECTION IS USED FOR Vincristine sulfate belongs to a group of anticancer medicines called Vinca alkaloids. It is used for the treatment of various cancers. Vincristine stops the cancer cells growing and eventually kills them. Vincristine is used to treat certain cancers, including: • acute leukaemia • Hodgkin’s disease • non-Hodgkin’s disease • rhabdomyosarcoma • neuroblastoma • Wilm’s tumour • bone cancer • mycosis fungoides • Ewing’s sarcoma • uterine or cervical cancer • breast cancer • malignant melanoma • lung cancer • gynaecological childhood tumours Your doctor may have prescribed vincristine for another reason. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU. BEFORE YOU ARE GIVEN VINCRISTINE SULFATE INJECTION _WHEN YOU MUST NOT BE GIVEN_ _IT_ DO NOT USE VINCRISTINE SULFATE INJECTION IF: • you have an allergy to vincristine or any of the ingredients listed at the end of this leaflet • you have an allergy to any of the Vinca Alkaloids medicines eg. Vinblastine and Vindesine • you suffer from Charcot-Marie- Tooth-Syndrome. This is a type o Read the complete document
Version: pfpvinci10921 Supersedes: pfpvinci10321 Page 1 of 16 AUSTRALIAN PRODUCT INFORMATION – VINCRISTINE SULFATE INJECTION 1. NAME OF THE MEDICINE Vincristine sulfate 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Vincristine Sulfate Injection contains 1 mg/mL of vincristine sulfate. For the full list of excipients, see Section 6.1 List of excipients. 3. PHARMACEUTICAL FORM Solution for injection. Vincristine Sulfate Injection is a sterile, hypertonic, preservative-free solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Vincristine is used primarily in the treatment of acute leukaemia, usually as a component of various chemotherapeutic regimens. It has also been used as part of combination therapy in the treatment of Hodgkin’s disease, non-Hodgkin’s malignant lymphomas, rhabdomyosarcoma, neuroblastoma, Wilm’s tumour, osteogenic sarcoma, mycosis fungoides, Ewing’s sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma of the lung and gynaecological tumours of childhood. Vincristine may be useful in patients with true idiopathic thrombocytopenic purpura resistant to the usual treatment, but is not recommended as primary treatment for this disorder. 4.2 DOSE AND METHOD OF ADMINISTRATION This preparation is for intravenous use only and is usually administered at weekly intervals. It can be fatal if administered intrathecally (see sections 4.3 Contraindications and 4.4 Special warnings and precautions for use). Vincristine should not be given intramuscularly, subcutaneously or intrathecally. Intrathecal use of vincristine usually results in death. When dispensed, flexible plastic containers containing this product should be labelled: FOR INTRAVENOUS USE ONLY. FATAL IF GIVEN BY ANY OTHER ROUTE. Version: pfpvinci10921 Supersedes: pfpvinci10321 Page 2 of 16 DOSAGE Neurotoxicity appears to be dose related. Extreme care must be used in calculating and administrating the dose of vincristine since overdosage may have very serious or fatal outcome (see section 4.9 O Read the complete document